|
1
|
Ferlay J, Shin HR, Bray F, et al: GLOBOCAN
2008 v20, Cancer Incidence and Mortality Worldwide. International
Agency for Research on Cancer; Lyon: 2010, http://globocan.iarc.fr.
|
|
2
|
Murali R, Soslow RA and Weigelt B:
Classification of endometrial carcinoma: more than two types.
Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marumoto T, Zhang D and Saya H: Aurora-A -
a guardian of poles. Nat Rev Cancer. 5:42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Glover DM, Leibowitz MH, McLean DA and
Parry H: Mutations in aurora prevent centrosome separation leading
to the formation of monopolar spindles. Cell. 81:95–105. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou H, Kuang J, Zhong L, et al: Tumour
amplified kinase STK15/BTAK induces centrosome amplification,
aneuploidy and transformation. Nat Genet. 20:189–193. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Katayama H, Brinkley WR and Sen S: The
Aurora kinases: role in cell transformation and tumorigenesis.
Cancer Metastasis Rev. 22:451–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katayama H, Sasai K, Kawai H, et al:
Phosphorylation by aurora kinase A induces Mdm2-mediated
destabilization and inhibition of p53. Nat Genet. 36:55–62. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cazales M, Schmitt E, Montembault E,
Dozier C, Prigent C and Ducommun B: CDC25B phosphorylation by
Aurora-A occurs at the G2/M transition and is inhibited by DNA
damage. Cell Cycle. 4:1233–1238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishida N, Nagasaka T, Kashiwagi K, Boland
CR and Goel A: High copy amplification of the Aurora-A gene is
associated with chromosomal instability phenotype in human
colorectal cancers. Cancer Biol Ther. 6:525–533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sen S, Zhou H, Zhang RD, et al:
Amplification/overexpression of a mitotic kinase gene in human
bladder cancer. J Natl Cancer Inst. 94:1320–1329. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li D, Zhu J, Firozi PF, et al:
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human
pancreatic cancer. Clin Cancer Res. 9:991–997. 2003.PubMed/NCBI
|
|
13
|
Sakakura C, Hagiwara A, Yasuoka R, et al:
Tumour-amplified kinase BTAK is amplified and overexpressed in
gastric cancers with possible involvement in aneuploid formation.
Br J Cancer. 84:824–831. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sen S, Zhou H and White RA: A putative
serine/threonine kinase encoding gene BTAK on chromosome 20q13 is
amplified and overexpressed in human breast cancer cell lines.
Oncogene. 14:2195–2200. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Landen CN Jr, Lin YG, Immaneni A, et al:
Overexpression of the centrosomal protein Aurora-A kinase is
associated with poor prognosis in epithelial ovarian cancer
patients. Clin Cancer Res. 13:4098–4104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lassmann S, Shen Y, Jütting U, et al:
Predictive value of Aurora-A/STK15 expression for late stage
epithelial ovarian cancer patients treated by adjuvant
chemotherapy. Clin Cancer Res. 13:4083–4091. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Umene K, Banno K, Kisu I, et al: Aurora
kinase inhibitors: potential molecular-targeted drugs for
gynecologic malignant tumors. Biomed Rep. 1:335–340. 2013.
|
|
18
|
Do TV, Xiao F, Bickel LE, et al: Aurora
kinase A mediates epithelial ovarian cancer cell migration and
adhesion. Oncogene. 33:539–549. 2014. View Article : Google Scholar
|
|
19
|
Kurai M, Shiozawa T, Shih HC, et al:
Expression of Aurora kinases A and B in normal, hyperplastic, and
malignant human endometrium: Aurora B as a predictor for poor
prognosis in endometrial carcinoma. Hum Pathol. 36:1281–1288. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moreno-Bueno G, Sánchez-Estévez C, Cassia
R, et al: Differential gene expression profile in endometrioid and
nonendometrioid endometrial carcinoma: STK15 is frequently
overexpressed and amplified in nonendometrioid carcinomas. Cancer
Res. 63:5697–5702. 2003.PubMed/NCBI
|
|
21
|
Tanaka E, Hashimoto Y, Ito T, et al: The
clinical significance of Aurora-A/STK15/BTAK expression in human
esophageal squamous cell carcinoma. Clin Cancer Res. 11:1827–1834.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Anand S, Penrhyn-Lowe S and Venkitaraman
AR: AURORA-A amplification overrides the mitotic spindle assembly
checkpoint, inducing resistance to Taxol. Cancer Cell. 3:51–62.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tanaka E, Hashimoto Y, Ito T, et al: The
suppression of aurora-A/STK15/BTAK expression enhances
chemosensitivity to docetaxel in human esophageal squamous cell
carcinoma. Clin Cancer Res. 13:1331–1340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Tang K, Zhang H, Zhang Y, Zhou W and
Chen X: Function of Aurora kinase A in Taxol-resistant breast
cancer and its correlation with P-gp. Mol Med Rep. 4:739–746.
2011.PubMed/NCBI
|
|
25
|
Cammareri P, Scopelliti A, Todaro M, et
al: Aurora-a is essential for the tumorigenic capacity and
chemoresistance of colorectal cancer stem cells. Cancer Res.
70:4655–4665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hata T, Furukawa T, Sunamura M, et al: RNA
interference targeting aurora kinase a suppresses tumor growth and
enhances the taxane chemosensitivity in human pancreatic cancer
cells. Cancer Res. 65:2899–2905. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang F, Guo X, Yang G, Rosen DG and Liu J:
AURKA and BRCA2 expression highly correlate with prognosis of
endometrioid ovarian carcinoma. Mod Pathol. 24:836–845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du J and Hannon GJ: Suppression of
p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion.
Proc Natl Acad Sci USA. 101:8975–8980. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Furukawa T, Kanai N, Shiwaku HO, Soga N,
Uehara A and Horii A: AURKA is one of the downstream targets of
MAPK1/ERK2 in pancreatic cancer. Oncogene. 25:4831–4839. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang G, Chang B, Yang F, et al: Aurora
kinase A promotes ovarian tumorigenesis through dysregulation of
the cell cycle and suppression of BRCA2. Clin Cancer Res.
16:3171–3181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goos JA, Coupe VM, Diosdado B, et al:
Aurora kinase A (AURKA) expression in colorectal cancer liver
metastasis is associated with poor prognosis. Br J Cancer.
109:2445–2452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamamoto S, Yamamoto-Ibusuki M, Yamamoto
Y, Fujiwara S and Iwase H: A comprehensive analysis of Aurora A;
transcript levels are the most reliable in association with
proliferation and prognosis in breast cancer. BMC Cancer.
13:2172013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yen CC, Yeh CN, Cheng CT, et al:
Integrating bioinformatics and clinicopathological research of
gastrointestinal stromal tumors: identification of Aurora kinase A
as a poor risk marker. Ann Surg Oncol. 19:3491–3499. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Royce ME, Xia W, Sahin AA, et al:
STK15/Aurora-A expression in primary breast tumors is correlated
with nuclear grade but not with prognosis. Cancer. 100:12–19. 2004.
View Article : Google Scholar
|
|
35
|
Hamada M, Yakushijin Y, Ohtsuka M,
Kakimoto M, Yasukawa M and Fujita S: Aurora2/BTAK/STK15 is involved
in cell cycle checkpoint and cell survival of aggressive
non-Hodgkin’s lymphoma. Br J Haematol. 121:439–447. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen SS, Chang PC, Cheng YW, Tang FM and
Lin YS: Suppression of the STK15 oncogenic activity requires a
transactivation-independent p53 function. EMBO J. 21:4491–4499.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Q, Kaneko S, Yang L, et al: Aurora-A
abrogation of p53 DNA binding and transactivation activity by
phosphorylation of serine 215. J Biol Chem. 279:52175–52182. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tatsuka M, Sato S, Kitajima S, et al:
Overexpression of Aurora-A potentiates HRAS-mediated oncogenic
transformation and is implicated in oral carcinogenesis. Oncogene.
24:1122–1127. 2005. View Article : Google Scholar
|
|
39
|
Guan Z, Wang XR, Zhu XF, et al: Aurora-A,
a negative prognostic marker, increases migration and decreases
radiosensitivity in cancer cells. Cancer Res. 67:10436–10444. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang H, He L, Kruk P, Nicosia SV and Cheng
JQ: Aurora-A induces cell survival and chemoresistance by
activation of Akt through a p53-dependent manner in ovarian cancer
cells. Int J Cancer. 119:2304–2312. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wan XB, Long ZJ, Yan M, et al: Inhibition
of Aurora-A suppresses epithelial-mesenchymal transition and
invasion by downregulating MAPK in nasopharyngeal carcinoma cells.
Carcinogenesis. 29:1930–1937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jeng YM, Peng SY, Lin CY and Hsu HC:
Overexpression and amplification of Aurora-A in hepatocellular
carcinoma. Clin Cancer Res. 10:2065–2071. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lin Y, Richards FM, Krippendorff BF, et
al: Paclitaxel and CYC3, an Aurora kinase A inhibitor, synergise in
pancreatic cancer cells but not bone marrow precursor cells. Br J
Cancer. 107:1692–1701. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Long M, Yin G, Liu L, et al:
Adenovirus-mediated Aurora A shRNA driven by stathmin promoter
suppressed tumor growth and enhanced paclitaxel chemotherapy
sensitivity in human breast carcinoma cells. Cancer Gene Ther.
19:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee HH, Zhu Y, Govindasamy KM and Gopalan
G: Down-regulation of Aurora-A overrides estrogen-mediated growth
and chemoresistance in breast cancer cells. Endocr Relat Cancer.
15:765–775. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Agnese V, Bazan V, Fiorentino FP, et al:
The role of Aurora-A inhibitors in cancer therapy. Ann Oncol.
18(Suppl 6): vi47–vi52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gautschi O, Heighway J, Mack PC, Purnell
PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug
targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
